Updated: 07/23/2014 6:14 PM
Created: 07/23/2014 6:13 PM WDIO.com
WASHINGTON (AP) - The Food and Drug Administration has approved a new combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts.
Purdue Pharma's new drug Targiniq ER is an extended release tablet that combines oxycodone - the active ingredient in OxyContin - with the drug naloxone. FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications.
If abusers crush the tablets for snorting or injecting naloxone blocks the euphoric effects of oxycodone, making the drug more difficult to abuse. Naloxone is currently used to reverse the overdose effects of opioids, highly addictive painkilling drugs including morphine, methadone, codeine and others.
The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most frequent method of painkiller abuse.
The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse. Deaths linked to addictive medications like OxyContin and Vicodin have quadrupled since 1990 to an estimated 16,500 in 2010, the most recent year for which the Centers for Disease Control and Prevention reports figures.
Doctors prescribe opioids for a wide range of ailments, from post-surgical pain to arthritis and migraines.
Stamford, Connecticut-based Purdue has often been cited by public health advocates as a key contributor to the overprescribing of opioids. In 2007, Purdue Pharma and three of its executives paid $634 million and pleaded guilty to charges of misleading the public about the safety and addictiveness of OxyContin.
Since then the company introduced a harder-to-abuse version of OxyContin that is designed to resist crushing, chewing and dissolving.
"The FDA is committed to combatting the misuse and abuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the public health crisis of prescription drug abuse in the U.S.," said FDA's Dr. Sharon Hertz.
The FDA is requiring Purdue to conduct long-term follow-up studies tracking rates of abuse, addiction, overdose and death with Targiniq. Those requirements are standard for all extended release opioid drugs approved in the U.S.
(Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
$36 Million Housing, Retail Development Planned for Duluth
Alongside Harbor Bay Real Estate Developers, city leaders announced plans Friday for a $36 million mixed-use luxury multifamily and retail project on London Road and 21st Ave. E. in Duluth.
The Touchstone Awards: Mentor Superior
Mentor Superior has already matched up 40 kids with mentors. Their waiting list is about that long as well. Their work has been recognized by the Duluth Superior Area Community Foundation.
Itasca Co. Man Charged in Infant Son's Death
Authorities have charged a rural Itasca County man in connection with the death of his infant son. An autopsy determined the 2 1/2 month old boy suffered blunt force trauma.
Woman Charged with Murder after Stabbing in Stoney Brook Township
There is new development in the murder case on the Fond du Lac Reservation. The husband of the victim has been released, and he is facing no charges. Instead, the woman who police had been searching for, Lydia Marie Barney, has been charged with second degree murder.
Wisconsin Health Officials Start Ebola Hotline
The state Department of Health Services announced Friday that the line is for fielding questions Wisconsin residents have about the Ebola virus. The toll-free number is 844-684-1064.